nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP2C8—Levothyroxine—hypothyroidism	0.177	0.42	CbGbCtD
Irbesartan—CYP2C8—Liotrix—hypothyroidism	0.173	0.41	CbGbCtD
Irbesartan—CYP3A4—Levothyroxine—hypothyroidism	0.0717	0.17	CbGbCtD
Irbesartan—Cardio-respiratory arrest—Liothyronine—hypothyroidism	0.0256	0.0749	CcSEcCtD
Irbesartan—Distention—Liotrix—hypothyroidism	0.014	0.041	CcSEcCtD
Irbesartan—JUN—nerve—hypothyroidism	0.0119	0.0744	CbGeAlD
Irbesartan—Tracheobronchitis—Liotrix—hypothyroidism	0.011	0.032	CcSEcCtD
Irbesartan—Cardio-respiratory arrest—Liotrix—hypothyroidism	0.00926	0.0271	CcSEcCtD
Irbesartan—Gastric irritation—Liotrix—hypothyroidism	0.00853	0.0249	CcSEcCtD
Irbesartan—CYP1A2—urine—hypothyroidism	0.00657	0.0412	CbGeAlD
Irbesartan—Epigastric discomfort—Liotrix—hypothyroidism	0.00629	0.0184	CcSEcCtD
Irbesartan—CYP2C9—urine—hypothyroidism	0.00624	0.0391	CbGeAlD
Irbesartan—Angina pectoris—Liothyronine—hypothyroidism	0.0056	0.0163	CcSEcCtD
Irbesartan—Acute coronary syndrome—Liothyronine—hypothyroidism	0.00505	0.0147	CcSEcCtD
Irbesartan—Myocardial infarction—Liothyronine—hypothyroidism	0.00502	0.0147	CcSEcCtD
Irbesartan—EDNRA—adrenal cortex—hypothyroidism	0.005	0.0313	CbGeAlD
Irbesartan—EDNRA—heart—hypothyroidism	0.00483	0.0303	CbGeAlD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—POU1F1—hypothyroidism	0.00483	0.0627	CbGpPWpGaD
Irbesartan—CYP3A4—urine—hypothyroidism	0.00476	0.0298	CbGeAlD
Irbesartan—CYP2D6—urine—hypothyroidism	0.00468	0.0293	CbGeAlD
Irbesartan—JUN—adrenal cortex—hypothyroidism	0.00456	0.0286	CbGeAlD
Irbesartan—UGT1A3—liver—hypothyroidism	0.00454	0.0285	CbGeAlD
Irbesartan—JUN—heart—hypothyroidism	0.00441	0.0276	CbGeAlD
Irbesartan—Wheezing—Levothyroxine—hypothyroidism	0.00437	0.0128	CcSEcCtD
Irbesartan—Wheezing—Dextrothyroxine—hypothyroidism	0.00437	0.0128	CcSEcCtD
Irbesartan—Feeling hot—Liotrix—hypothyroidism	0.00421	0.0123	CcSEcCtD
Irbesartan—JUN—cardiovascular system—hypothyroidism	0.00416	0.0261	CbGeAlD
Irbesartan—Arrhythmia—Liothyronine—hypothyroidism	0.00411	0.012	CcSEcCtD
Irbesartan—EDNRA—pituitary gland—hypothyroidism	0.00404	0.0253	CbGeAlD
Irbesartan—Tenderness—Liotrix—hypothyroidism	0.00379	0.0111	CcSEcCtD
Irbesartan—JUN—gonad—hypothyroidism	0.00377	0.0237	CbGeAlD
Irbesartan—JUN—pituitary gland—hypothyroidism	0.00368	0.0231	CbGeAlD
Irbesartan—EDNRA—adrenal gland—hypothyroidism	0.00361	0.0226	CbGeAlD
Irbesartan—EDNRA—thyroid gland—hypothyroidism	0.00348	0.0218	CbGeAlD
Irbesartan—Increased appetite—Dextrothyroxine—hypothyroidism	0.00347	0.0101	CcSEcCtD
Irbesartan—Increased appetite—Levothyroxine—hypothyroidism	0.00347	0.0101	CcSEcCtD
Irbesartan—Hypertension—Liothyronine—hypothyroidism	0.00346	0.0101	CcSEcCtD
Irbesartan—AGTR1—adrenal cortex—hypothyroidism	0.00343	0.0215	CbGeAlD
Irbesartan—EDNRA—female gonad—hypothyroidism	0.00336	0.0211	CbGeAlD
Irbesartan—AGTR1—heart—hypothyroidism	0.00332	0.0208	CbGeAlD
Irbesartan—JUN—adrenal gland—hypothyroidism	0.00329	0.0206	CbGeAlD
Irbesartan—JUN—blood—hypothyroidism	0.00329	0.0206	CbGeAlD
Irbesartan—Affect lability—Dextrothyroxine—hypothyroidism	0.00321	0.00938	CcSEcCtD
Irbesartan—Affect lability—Levothyroxine—hypothyroidism	0.00321	0.00938	CcSEcCtD
Irbesartan—Wheezing—Liotrix—hypothyroidism	0.00321	0.00938	CcSEcCtD
Irbesartan—Tachycardia—Liothyronine—hypothyroidism	0.00319	0.00931	CcSEcCtD
Irbesartan—JUN—thyroid gland—hypothyroidism	0.00317	0.0199	CbGeAlD
Irbesartan—AGTR1—cardiovascular system—hypothyroidism	0.00313	0.0196	CbGeAlD
Irbesartan—Blood urea increased—Liotrix—hypothyroidism	0.00312	0.00912	CcSEcCtD
Irbesartan—Mood swings—Dextrothyroxine—hypothyroidism	0.00309	0.00903	CcSEcCtD
Irbesartan—Mood swings—Levothyroxine—hypothyroidism	0.00309	0.00903	CcSEcCtD
Irbesartan—JUN—female gonad—hypothyroidism	0.00307	0.0192	CbGeAlD
Irbesartan—Hypotension—Liothyronine—hypothyroidism	0.00305	0.00892	CcSEcCtD
Irbesartan—EDNRA—testis—hypothyroidism	0.00298	0.0187	CbGeAlD
Irbesartan—Lightheadedness—Liotrix—hypothyroidism	0.00296	0.00864	CcSEcCtD
Irbesartan—Muscular weakness—Dextrothyroxine—hypothyroidism	0.00288	0.00841	CcSEcCtD
Irbesartan—Muscular weakness—Levothyroxine—hypothyroidism	0.00288	0.00841	CcSEcCtD
Irbesartan—Dysphagia—Dextrothyroxine—hypothyroidism	0.00282	0.00824	CcSEcCtD
Irbesartan—Dysphagia—Levothyroxine—hypothyroidism	0.00282	0.00824	CcSEcCtD
Irbesartan—JUN—TSH signaling pathway—PAX8—hypothyroidism	0.0028	0.0364	CbGpPWpGaD
Irbesartan—AGTR1—Arf6 trafficking events—CLTC—hypothyroidism	0.00278	0.0362	CbGpPWpGaD
Irbesartan—AGTR1—pituitary gland—hypothyroidism	0.00277	0.0174	CbGeAlD
Irbesartan—Angina pectoris—Dextrothyroxine—hypothyroidism	0.00275	0.00803	CcSEcCtD
Irbesartan—Angina pectoris—Levothyroxine—hypothyroidism	0.00275	0.00803	CcSEcCtD
Irbesartan—Swelling—Liotrix—hypothyroidism	0.00272	0.00795	CcSEcCtD
Irbesartan—JUN—testis—hypothyroidism	0.00272	0.0171	CbGeAlD
Irbesartan—AGTR1—Arf6 signaling events—TSHR—hypothyroidism	0.00271	0.0353	CbGpPWpGaD
Irbesartan—EDNRA—Prostaglandin Synthesis and Regulation—PRL—hypothyroidism	0.00259	0.0336	CbGpPWpGaD
Irbesartan—Body temperature increased—Liothyronine—hypothyroidism	0.00258	0.00754	CcSEcCtD
Irbesartan—JUN—liver—hypothyroidism	0.00257	0.0161	CbGeAlD
Irbesartan—Increased appetite—Liotrix—hypothyroidism	0.00256	0.00746	CcSEcCtD
Irbesartan—Renal impairment—Liotrix—hypothyroidism	0.00252	0.00737	CcSEcCtD
Irbesartan—JUN—cerebellum—hypothyroidism	0.00251	0.0158	CbGeAlD
Irbesartan—Acute coronary syndrome—Dextrothyroxine—hypothyroidism	0.00248	0.00724	CcSEcCtD
Irbesartan—Acute coronary syndrome—Levothyroxine—hypothyroidism	0.00248	0.00724	CcSEcCtD
Irbesartan—AGTR1—adrenal gland—hypothyroidism	0.00248	0.0155	CbGeAlD
Irbesartan—AGTR1—blood—hypothyroidism	0.00248	0.0155	CbGeAlD
Irbesartan—Myocardial infarction—Levothyroxine—hypothyroidism	0.00247	0.0072	CcSEcCtD
Irbesartan—Myocardial infarction—Dextrothyroxine—hypothyroidism	0.00247	0.0072	CcSEcCtD
Irbesartan—Cerebrovascular accident—Liotrix—hypothyroidism	0.00245	0.00716	CcSEcCtD
Irbesartan—AGTR1—thyroid gland—hypothyroidism	0.00239	0.015	CbGeAlD
Irbesartan—Affect lability—Liotrix—hypothyroidism	0.00236	0.0069	CcSEcCtD
Irbesartan—Mood swings—Liotrix—hypothyroidism	0.00227	0.00664	CcSEcCtD
Irbesartan—Hypokalaemia—Liotrix—hypothyroidism	0.00219	0.00638	CcSEcCtD
Irbesartan—AGTR1—Arf6 trafficking events—TSHR—hypothyroidism	0.00214	0.0279	CbGpPWpGaD
Irbesartan—Muscular weakness—Liotrix—hypothyroidism	0.00212	0.00619	CcSEcCtD
Irbesartan—Flushing—Dextrothyroxine—hypothyroidism	0.0021	0.00612	CcSEcCtD
Irbesartan—Flushing—Levothyroxine—hypothyroidism	0.0021	0.00612	CcSEcCtD
Irbesartan—Abdominal distension—Liotrix—hypothyroidism	0.00209	0.0061	CcSEcCtD
Irbesartan—Dysphagia—Liotrix—hypothyroidism	0.00208	0.00606	CcSEcCtD
Irbesartan—AGTR1—testis—hypothyroidism	0.00205	0.0128	CbGeAlD
Irbesartan—Angina pectoris—Liotrix—hypothyroidism	0.00202	0.0059	CcSEcCtD
Irbesartan—Arrhythmia—Dextrothyroxine—hypothyroidism	0.00202	0.00589	CcSEcCtD
Irbesartan—Arrhythmia—Levothyroxine—hypothyroidism	0.00202	0.00589	CcSEcCtD
Irbesartan—AGTR1—liver—hypothyroidism	0.00194	0.0121	CbGeAlD
Irbesartan—Tension—Levothyroxine—hypothyroidism	0.00193	0.00563	CcSEcCtD
Irbesartan—Tension—Dextrothyroxine—hypothyroidism	0.00193	0.00563	CcSEcCtD
Irbesartan—Nervousness—Levothyroxine—hypothyroidism	0.00191	0.00558	CcSEcCtD
Irbesartan—Nervousness—Dextrothyroxine—hypothyroidism	0.00191	0.00558	CcSEcCtD
Irbesartan—EDNRA—Peptide GPCRs—TSHR—hypothyroidism	0.0019	0.0247	CbGpPWpGaD
Irbesartan—Tremor—Levothyroxine—hypothyroidism	0.00184	0.00538	CcSEcCtD
Irbesartan—Tremor—Dextrothyroxine—hypothyroidism	0.00184	0.00538	CcSEcCtD
Irbesartan—Acute coronary syndrome—Liotrix—hypothyroidism	0.00182	0.00533	CcSEcCtD
Irbesartan—Renal failure—Liotrix—hypothyroidism	0.00182	0.00531	CcSEcCtD
Irbesartan—Myocardial infarction—Liotrix—hypothyroidism	0.00181	0.0053	CcSEcCtD
Irbesartan—Agitation—Levothyroxine—hypothyroidism	0.00181	0.00528	CcSEcCtD
Irbesartan—Agitation—Dextrothyroxine—hypothyroidism	0.00181	0.00528	CcSEcCtD
Irbesartan—Angioedema—Levothyroxine—hypothyroidism	0.0018	0.00525	CcSEcCtD
Irbesartan—Angioedema—Dextrothyroxine—hypothyroidism	0.0018	0.00525	CcSEcCtD
Irbesartan—JUN—Validated transcriptional targets of AP1 family members Fra1 and Fra2—BGLAP—hypothyroidism	0.00174	0.0226	CbGpPWpGaD
Irbesartan—JUN—Regulation of nuclear SMAD2/3 signaling—NKX2-5—hypothyroidism	0.0017	0.022	CbGpPWpGaD
Irbesartan—Arthralgia—Levothyroxine—hypothyroidism	0.00167	0.00489	CcSEcCtD
Irbesartan—Arthralgia—Dextrothyroxine—hypothyroidism	0.00167	0.00489	CcSEcCtD
Irbesartan—Anxiety—Levothyroxine—hypothyroidism	0.00167	0.00487	CcSEcCtD
Irbesartan—Anxiety—Dextrothyroxine—hypothyroidism	0.00167	0.00487	CcSEcCtD
Irbesartan—Hypoaesthesia—Liotrix—hypothyroidism	0.00165	0.00483	CcSEcCtD
Irbesartan—CYP2C9—heart—hypothyroidism	0.0016	0.01	CbGeAlD
Irbesartan—Shock—Levothyroxine—hypothyroidism	0.00158	0.00461	CcSEcCtD
Irbesartan—Shock—Dextrothyroxine—hypothyroidism	0.00158	0.00461	CcSEcCtD
Irbesartan—Tachycardia—Levothyroxine—hypothyroidism	0.00157	0.00457	CcSEcCtD
Irbesartan—Tachycardia—Dextrothyroxine—hypothyroidism	0.00157	0.00457	CcSEcCtD
Irbesartan—Hyperhidrosis—Levothyroxine—hypothyroidism	0.00155	0.00453	CcSEcCtD
Irbesartan—Hyperhidrosis—Dextrothyroxine—hypothyroidism	0.00155	0.00453	CcSEcCtD
Irbesartan—Flushing—Liotrix—hypothyroidism	0.00154	0.0045	CcSEcCtD
Irbesartan—CYP2C9—cardiovascular system—hypothyroidism	0.00151	0.00946	CbGeAlD
Irbesartan—CYP2C8—pituitary gland—hypothyroidism	0.0015	0.00942	CbGeAlD
Irbesartan—UGT1A3—NRF2 pathway—SLC5A7—hypothyroidism	0.0015	0.0195	CbGpPWpGaD
Irbesartan—AGTR1—Peptide GPCRs—TSHR—hypothyroidism	0.00149	0.0194	CbGpPWpGaD
Irbesartan—Arrhythmia—Liotrix—hypothyroidism	0.00148	0.00433	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Levothyroxine—hypothyroidism	0.00146	0.00427	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Dextrothyroxine—hypothyroidism	0.00146	0.00427	CcSEcCtD
Irbesartan—PTGS1—heart—hypothyroidism	0.00146	0.00915	CbGeAlD
Irbesartan—Dyspnoea—Dextrothyroxine—hypothyroidism	0.00143	0.00418	CcSEcCtD
Irbesartan—Dyspnoea—Levothyroxine—hypothyroidism	0.00143	0.00418	CcSEcCtD
Irbesartan—Flatulence—Liotrix—hypothyroidism	0.00142	0.00416	CcSEcCtD
Irbesartan—Tension—Liotrix—hypothyroidism	0.00142	0.00414	CcSEcCtD
Irbesartan—Dysgeusia—Liotrix—hypothyroidism	0.00142	0.00414	CcSEcCtD
Irbesartan—JUN—SIDS Susceptibility Pathways—DLX2—hypothyroidism	0.00141	0.0183	CbGpPWpGaD
Irbesartan—Nervousness—Liotrix—hypothyroidism	0.0014	0.0041	CcSEcCtD
Irbesartan—Fatigue—Levothyroxine—hypothyroidism	0.00138	0.00404	CcSEcCtD
Irbesartan—Fatigue—Dextrothyroxine—hypothyroidism	0.00138	0.00404	CcSEcCtD
Irbesartan—PTGS1—cardiovascular system—hypothyroidism	0.00138	0.00863	CbGeAlD
Irbesartan—JUN—Osteopontin-mediated events—VAV3—hypothyroidism	0.00137	0.0178	CbGpPWpGaD
Irbesartan—Vision blurred—Liotrix—hypothyroidism	0.00136	0.00398	CcSEcCtD
Irbesartan—Tremor—Liotrix—hypothyroidism	0.00135	0.00396	CcSEcCtD
Irbesartan—CYP2C8—blood—hypothyroidism	0.00134	0.00842	CbGeAlD
Irbesartan—Agitation—Liotrix—hypothyroidism	0.00133	0.00388	CcSEcCtD
Irbesartan—Feeling abnormal—Dextrothyroxine—hypothyroidism	0.00132	0.00386	CcSEcCtD
Irbesartan—Feeling abnormal—Levothyroxine—hypothyroidism	0.00132	0.00386	CcSEcCtD
Irbesartan—Angioedema—Liotrix—hypothyroidism	0.00132	0.00386	CcSEcCtD
Irbesartan—Gastrointestinal pain—Levothyroxine—hypothyroidism	0.00131	0.00383	CcSEcCtD
Irbesartan—Gastrointestinal pain—Dextrothyroxine—hypothyroidism	0.00131	0.00383	CcSEcCtD
Irbesartan—Syncope—Liotrix—hypothyroidism	0.0013	0.00379	CcSEcCtD
Irbesartan—JUN—FGF signaling pathway—BGLAP—hypothyroidism	0.00129	0.0167	CbGpPWpGaD
Irbesartan—Urticaria—Levothyroxine—hypothyroidism	0.00127	0.00372	CcSEcCtD
Irbesartan—Urticaria—Dextrothyroxine—hypothyroidism	0.00127	0.00372	CcSEcCtD
Irbesartan—Loss of consciousness—Liotrix—hypothyroidism	0.00127	0.00371	CcSEcCtD
Irbesartan—Body temperature increased—Levothyroxine—hypothyroidism	0.00127	0.0037	CcSEcCtD
Irbesartan—Body temperature increased—Dextrothyroxine—hypothyroidism	0.00127	0.0037	CcSEcCtD
Irbesartan—Abdominal pain—Levothyroxine—hypothyroidism	0.00127	0.0037	CcSEcCtD
Irbesartan—Abdominal pain—Dextrothyroxine—hypothyroidism	0.00127	0.0037	CcSEcCtD
Irbesartan—CYP1A2—blood—hypothyroidism	0.00126	0.00788	CbGeAlD
Irbesartan—Hypertension—Liotrix—hypothyroidism	0.00125	0.00365	CcSEcCtD
Irbesartan—Chest pain—Liotrix—hypothyroidism	0.00123	0.0036	CcSEcCtD
Irbesartan—Arthralgia—Liotrix—hypothyroidism	0.00123	0.0036	CcSEcCtD
Irbesartan—Anxiety—Liotrix—hypothyroidism	0.00123	0.00358	CcSEcCtD
Irbesartan—JUN—TSH signaling pathway—TSHR—hypothyroidism	0.00122	0.0159	CbGpPWpGaD
Irbesartan—JUN—TSH signaling pathway—TSHB—hypothyroidism	0.00122	0.0159	CbGpPWpGaD
Irbesartan—PTGS1—pituitary gland—hypothyroidism	0.00122	0.00764	CbGeAlD
Irbesartan—CYP1A2—thyroid gland—hypothyroidism	0.00121	0.0076	CbGeAlD
Irbesartan—CYP2C9—blood—hypothyroidism	0.00119	0.00748	CbGeAlD
Irbesartan—Oedema—Liotrix—hypothyroidism	0.00118	0.00345	CcSEcCtD
Irbesartan—Anaphylactic shock—Liotrix—hypothyroidism	0.00118	0.00345	CcSEcCtD
Irbesartan—Infection—Liotrix—hypothyroidism	0.00117	0.00342	CcSEcCtD
Irbesartan—Shock—Liotrix—hypothyroidism	0.00116	0.00339	CcSEcCtD
Irbesartan—Tachycardia—Liotrix—hypothyroidism	0.00115	0.00336	CcSEcCtD
Irbesartan—Asthenia—Dextrothyroxine—hypothyroidism	0.00115	0.00336	CcSEcCtD
Irbesartan—Asthenia—Levothyroxine—hypothyroidism	0.00115	0.00336	CcSEcCtD
Irbesartan—Hyperhidrosis—Liotrix—hypothyroidism	0.00114	0.00333	CcSEcCtD
Irbesartan—Pruritus—Levothyroxine—hypothyroidism	0.00114	0.00332	CcSEcCtD
Irbesartan—Pruritus—Dextrothyroxine—hypothyroidism	0.00114	0.00332	CcSEcCtD
Irbesartan—Anorexia—Liotrix—hypothyroidism	0.00112	0.00329	CcSEcCtD
Irbesartan—CYP2C8—testis—hypothyroidism	0.00111	0.00696	CbGeAlD
Irbesartan—Hypotension—Liotrix—hypothyroidism	0.0011	0.00322	CcSEcCtD
Irbesartan—Diarrhoea—Dextrothyroxine—hypothyroidism	0.0011	0.00321	CcSEcCtD
Irbesartan—Diarrhoea—Levothyroxine—hypothyroidism	0.0011	0.00321	CcSEcCtD
Irbesartan—JUN—Regulation of retinoblastoma protein—BGLAP—hypothyroidism	0.00109	0.0142	CbGpPWpGaD
Irbesartan—PTGS1—adrenal gland—hypothyroidism	0.00109	0.00683	CbGeAlD
Irbesartan—PTGS1—blood—hypothyroidism	0.00109	0.00683	CbGeAlD
Irbesartan—Musculoskeletal discomfort—Liotrix—hypothyroidism	0.00108	0.00314	CcSEcCtD
Irbesartan—Paraesthesia—Liotrix—hypothyroidism	0.00106	0.0031	CcSEcCtD
Irbesartan—PTGS1—Prostaglandin Synthesis and Regulation—PRL—hypothyroidism	0.00106	0.0138	CbGpPWpGaD
Irbesartan—Dyspnoea—Liotrix—hypothyroidism	0.00105	0.00307	CcSEcCtD
Irbesartan—JUN—FCERI mediated MAPK activation—VAV3—hypothyroidism	0.00105	0.0137	CbGpPWpGaD
Irbesartan—PTGS1—thyroid gland—hypothyroidism	0.00105	0.00659	CbGeAlD
Irbesartan—CYP2C8—liver—hypothyroidism	0.00105	0.00658	CbGeAlD
Irbesartan—Decreased appetite—Liotrix—hypothyroidism	0.00103	0.003	CcSEcCtD
Irbesartan—Vomiting—Levothyroxine—hypothyroidism	0.00102	0.00298	CcSEcCtD
Irbesartan—Vomiting—Dextrothyroxine—hypothyroidism	0.00102	0.00298	CcSEcCtD
Irbesartan—Fatigue—Liotrix—hypothyroidism	0.00102	0.00297	CcSEcCtD
Irbesartan—PTGS1—female gonad—hypothyroidism	0.00102	0.00637	CbGeAlD
Irbesartan—EDNRA—G alpha (q) signalling events—TRH—hypothyroidism	0.00102	0.0132	CbGpPWpGaD
Irbesartan—Rash—Levothyroxine—hypothyroidism	0.00101	0.00295	CcSEcCtD
Irbesartan—Rash—Dextrothyroxine—hypothyroidism	0.00101	0.00295	CcSEcCtD
Irbesartan—Dermatitis—Levothyroxine—hypothyroidism	0.00101	0.00295	CcSEcCtD
Irbesartan—Dermatitis—Dextrothyroxine—hypothyroidism	0.00101	0.00295	CcSEcCtD
Irbesartan—Constipation—Liotrix—hypothyroidism	0.00101	0.00295	CcSEcCtD
Irbesartan—Headache—Levothyroxine—hypothyroidism	0.00101	0.00294	CcSEcCtD
Irbesartan—Headache—Dextrothyroxine—hypothyroidism	0.00101	0.00294	CcSEcCtD
Irbesartan—EDNRA—Peptide ligand-binding receptors—TRH—hypothyroidism	0.001	0.013	CbGpPWpGaD
Irbesartan—CYP1A2—liver—hypothyroidism	0.000983	0.00616	CbGeAlD
Irbesartan—Feeling abnormal—Liotrix—hypothyroidism	0.000973	0.00284	CcSEcCtD
Irbesartan—Gastrointestinal pain—Liotrix—hypothyroidism	0.000965	0.00282	CcSEcCtD
Irbesartan—Nausea—Levothyroxine—hypothyroidism	0.000953	0.00278	CcSEcCtD
Irbesartan—Nausea—Dextrothyroxine—hypothyroidism	0.000953	0.00278	CcSEcCtD
Irbesartan—Urticaria—Liotrix—hypothyroidism	0.000938	0.00274	CcSEcCtD
Irbesartan—Abdominal pain—Liotrix—hypothyroidism	0.000933	0.00272	CcSEcCtD
Irbesartan—Body temperature increased—Liotrix—hypothyroidism	0.000933	0.00272	CcSEcCtD
Irbesartan—CYP2C9—liver—hypothyroidism	0.000933	0.00585	CbGeAlD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—BGLAP—hypothyroidism	0.00092	0.012	CbGpPWpGaD
Irbesartan—CYP3A4—blood—hypothyroidism	0.00091	0.0057	CbGeAlD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000908	0.0118	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.000908	0.0118	CbGpPWpGaD
Irbesartan—PTGS1—testis—hypothyroidism	0.000901	0.00565	CbGeAlD
Irbesartan—CYP2D6—blood—hypothyroidism	0.000895	0.00561	CbGeAlD
Irbesartan—Hypersensitivity—Liotrix—hypothyroidism	0.000869	0.00254	CcSEcCtD
Irbesartan—JUN—TCR Signaling Pathway—SH2B3—hypothyroidism	0.000849	0.011	CbGpPWpGaD
Irbesartan—Asthenia—Liotrix—hypothyroidism	0.000847	0.00247	CcSEcCtD
Irbesartan—Pruritus—Liotrix—hypothyroidism	0.000835	0.00244	CcSEcCtD
Irbesartan—CYP2D6—female gonad—hypothyroidism	0.000835	0.00523	CbGeAlD
Irbesartan—JUN—Validated nuclear estrogen receptor alpha network—PRL—hypothyroidism	0.000827	0.0107	CbGpPWpGaD
Irbesartan—Diarrhoea—Liotrix—hypothyroidism	0.000807	0.00236	CcSEcCtD
Irbesartan—AGTR1—G alpha (q) signalling events—TRH—hypothyroidism	0.000797	0.0104	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—TRH—hypothyroidism	0.000787	0.0102	CbGpPWpGaD
Irbesartan—Dizziness—Liotrix—hypothyroidism	0.00078	0.00228	CcSEcCtD
Irbesartan—JUN—Circadian rythm related genes—NKX2-1—hypothyroidism	0.000777	0.0101	CbGpPWpGaD
Irbesartan—Vomiting—Liotrix—hypothyroidism	0.00075	0.00219	CcSEcCtD
Irbesartan—Rash—Liotrix—hypothyroidism	0.000744	0.00217	CcSEcCtD
Irbesartan—Dermatitis—Liotrix—hypothyroidism	0.000743	0.00217	CcSEcCtD
Irbesartan—CYP2D6—testis—hypothyroidism	0.00074	0.00464	CbGeAlD
Irbesartan—Headache—Liotrix—hypothyroidism	0.000739	0.00216	CcSEcCtD
Irbesartan—JUN—DNA Damage Response (only ATM dependent)—PIK3C2A—hypothyroidism	0.000728	0.00946	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TRH—hypothyroidism	0.000712	0.00926	CbGpPWpGaD
Irbesartan—CYP3A4—liver—hypothyroidism	0.000711	0.00446	CbGeAlD
Irbesartan—Nausea—Liotrix—hypothyroidism	0.000701	0.00205	CcSEcCtD
Irbesartan—CYP2D6—liver—hypothyroidism	0.0007	0.00439	CbGeAlD
Irbesartan—CYP2D6—cerebellum—hypothyroidism	0.000684	0.00429	CbGeAlD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—PRL—hypothyroidism	0.000678	0.00882	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000672	0.00874	CbGpPWpGaD
Irbesartan—UGT1A3—NRF2 pathway—SLC5A5—hypothyroidism	0.0006	0.0078	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000599	0.00779	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000599	0.00779	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—VAV3—hypothyroidism	0.000582	0.00757	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—PIK3C2A—hypothyroidism	0.000536	0.00696	CbGpPWpGaD
Irbesartan—EDNRA—G alpha (q) signalling events—AVP—hypothyroidism	0.000533	0.00693	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000528	0.00686	CbGpPWpGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—AVP—hypothyroidism	0.000527	0.00684	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—TRH—hypothyroidism	0.000512	0.00665	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000477	0.0062	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.00047	0.00611	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.00047	0.00611	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—TSHB—hypothyroidism	0.000456	0.00593	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—TSHR—hypothyroidism	0.000456	0.00593	CbGpPWpGaD
Irbesartan—AGTR1—G alpha (q) signalling events—AVP—hypothyroidism	0.000418	0.00544	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—AVP—hypothyroidism	0.000413	0.00537	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—POMC—hypothyroidism	0.000402	0.00522	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—TRH—hypothyroidism	0.000402	0.00522	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—VAV3—hypothyroidism	0.0004	0.0052	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—IGF1—hypothyroidism	0.000379	0.00493	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—hypothyroidism	0.000374	0.00486	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—VAV3—hypothyroidism	0.000364	0.00473	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000361	0.0047	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—TSHB—hypothyroidism	0.000358	0.00465	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—TSHR—hypothyroidism	0.000358	0.00465	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000353	0.00459	CbGpPWpGaD
Irbesartan—EDNRA—Peptide ligand-binding receptors—POMC—hypothyroidism	0.00035	0.00455	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—VAV3—hypothyroidism	0.000339	0.00441	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—IYD—hypothyroidism	0.000325	0.00422	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—IGF1—hypothyroidism	0.000317	0.00412	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—AVP—hypothyroidism	0.000295	0.00384	CbGpPWpGaD
Irbesartan—PTGS1—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000292	0.00379	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—TRH—hypothyroidism	0.000289	0.00376	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000277	0.0036	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ATP5O—hypothyroidism	0.000276	0.00359	CbGpPWpGaD
Irbesartan—UGT1A3—Biological oxidations—POMC—hypothyroidism	0.000275	0.00358	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—POMC—hypothyroidism	0.000275	0.00357	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—AVP—hypothyroidism	0.000269	0.0035	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—TRH—hypothyroidism	0.000263	0.00341	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—TPO—hypothyroidism	0.00026	0.00337	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—TSHB—hypothyroidism	0.000258	0.00335	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—TSHR—hypothyroidism	0.000258	0.00335	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000235	0.00305	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—TSHB—hypothyroidism	0.000234	0.00304	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—TSHR—hypothyroidism	0.000234	0.00304	CbGpPWpGaD
Irbesartan—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000233	0.00302	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—TRH—hypothyroidism	0.000227	0.00295	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—AVP—hypothyroidism	0.000211	0.00274	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—TRH—hypothyroidism	0.000206	0.00268	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—TSHB—hypothyroidism	0.000202	0.00263	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—TSHR—hypothyroidism	0.000202	0.00263	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—IGF1—hypothyroidism	0.000197	0.00256	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—IGF1—hypothyroidism	0.000196	0.00255	CbGpPWpGaD
Irbesartan—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000191	0.00248	CbGpPWpGaD
Irbesartan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000189	0.00246	CbGpPWpGaD
Irbesartan—CYP2C8—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000189	0.00245	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000184	0.00239	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—TSHB—hypothyroidism	0.000184	0.00239	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—TSHR—hypothyroidism	0.000184	0.00239	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—IYD—hypothyroidism	0.000183	0.00238	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CLTC—hypothyroidism	0.00018	0.00233	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—POMC—hypothyroidism	0.000179	0.00232	CbGpPWpGaD
Irbesartan—JUN—Immune System—CLTC—hypothyroidism	0.000163	0.00212	CbGpPWpGaD
Irbesartan—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000162	0.0021	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—VAV3—hypothyroidism	0.000158	0.00205	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ATP5O—hypothyroidism	0.000156	0.00202	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TRH—hypothyroidism	0.000155	0.00202	CbGpPWpGaD
Irbesartan—PTGS1—Biological oxidations—POMC—hypothyroidism	0.000155	0.00202	CbGpPWpGaD
Irbesartan—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000155	0.00201	CbGpPWpGaD
Irbesartan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000153	0.00199	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AVP—hypothyroidism	0.000152	0.00198	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TPO—hypothyroidism	0.000146	0.0019	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—VAV3—hypothyroidism	0.000143	0.00186	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CLTC—hypothyroidism	0.000141	0.00183	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—POMC—hypothyroidism	0.00014	0.00182	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TSHB—hypothyroidism	0.000138	0.0018	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TSHR—hypothyroidism	0.000138	0.0018	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AVP—hypothyroidism	0.000138	0.00179	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	0.000136	0.00176	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—VAV3—hypothyroidism	0.000132	0.00171	CbGpPWpGaD
Irbesartan—CYP1A2—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000131	0.0017	CbGpPWpGaD
Irbesartan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000125	0.00162	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—VAV3—hypothyroidism	0.000124	0.00161	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—SH2B3—hypothyroidism	0.000123	0.0016	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TRH—hypothyroidism	0.000122	0.00158	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—TSHB—hypothyroidism	0.00012	0.00156	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AVP—hypothyroidism	0.000119	0.00155	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—IYD—hypothyroidism	0.000118	0.00154	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—VAV3—hypothyroidism	0.000112	0.00146	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TSHB—hypothyroidism	0.000109	0.00141	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TSHR—hypothyroidism	0.000109	0.00141	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AVP—hypothyroidism	0.000108	0.00141	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—PIK3C2A—hypothyroidism	0.000107	0.00139	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CLTC—hypothyroidism	0.000105	0.00137	CbGpPWpGaD
Irbesartan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000101	0.00132	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—POMC—hypothyroidism	0.000101	0.00131	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ATP5O—hypothyroidism	0.0001	0.00131	CbGpPWpGaD
Irbesartan—CYP2C8—Biological oxidations—POMC—hypothyroidism	0.0001	0.0013	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—IYD—hypothyroidism	9.7e-05	0.00126	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—SH2B3—hypothyroidism	9.68e-05	0.00126	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—IYD—hypothyroidism	9.62e-05	0.00125	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TPO—hypothyroidism	9.45e-05	0.00123	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—POMC—hypothyroidism	9.17e-05	0.00119	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PRL—hypothyroidism	9.15e-05	0.00119	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TRH—hypothyroidism	9.1e-05	0.00118	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—SLC5A5—hypothyroidism	9e-05	0.00117	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	8.75e-05	0.00114	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VAV3—hypothyroidism	8.46e-05	0.0011	CbGpPWpGaD
Irbesartan—JUN—Immune System—PRL—hypothyroidism	8.29e-05	0.00108	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ATP5O—hypothyroidism	8.25e-05	0.00107	CbGpPWpGaD
Irbesartan—CYP2D6—Biological oxidations—POMC—hypothyroidism	8.22e-05	0.00107	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—IYD—hypothyroidism	8.22e-05	0.00107	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ATP5O—hypothyroidism	8.18e-05	0.00106	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AVP—hypothyroidism	8.15e-05	0.00106	CbGpPWpGaD
Irbesartan—CYP2C9—Biological oxidations—POMC—hypothyroidism	8.15e-05	0.00106	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TSHB—hypothyroidism	8.11e-05	0.00105	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TSHR—hypothyroidism	8.11e-05	0.00105	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—POMC—hypothyroidism	7.93e-05	0.00103	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TPO—hypothyroidism	7.76e-05	0.00101	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TPO—hypothyroidism	7.69e-05	0.000999	CbGpPWpGaD
Irbesartan—JUN—Immune System—VAV3—hypothyroidism	7.67e-05	0.000997	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SH2B3—hypothyroidism	7.23e-05	0.00094	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—POMC—hypothyroidism	7.2e-05	0.000935	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PRL—hypothyroidism	7.18e-05	0.000933	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	7.12e-05	0.000926	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ATP5O—hypothyroidism	6.99e-05	0.000908	CbGpPWpGaD
Irbesartan—CYP1A2—Biological oxidations—POMC—hypothyroidism	6.97e-05	0.000905	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TSHB—hypothyroidism	6.77e-05	0.00088	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VAV3—hypothyroidism	6.64e-05	0.000863	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TPO—hypothyroidism	6.57e-05	0.000854	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AVP—hypothyroidism	6.4e-05	0.000832	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—IYD—hypothyroidism	6.34e-05	0.000824	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3C2A—hypothyroidism	6.09e-05	0.000791	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3C2A—hypothyroidism	6.03e-05	0.000784	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	5.95e-05	0.000774	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—POMC—hypothyroidism	5.42e-05	0.000704	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ATP5O—hypothyroidism	5.39e-05	0.000701	CbGpPWpGaD
Irbesartan—CYP3A4—Biological oxidations—POMC—hypothyroidism	5.38e-05	0.000699	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PRL—hypothyroidism	5.36e-05	0.000697	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IGF1—hypothyroidism	5.21e-05	0.000677	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TPO—hypothyroidism	5.07e-05	0.000659	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SLC5A5—hypothyroidism	5.07e-05	0.000659	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VAV3—hypothyroidism	4.96e-05	0.000645	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AVP—hypothyroidism	4.78e-05	0.000621	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—POMC—hypothyroidism	4.71e-05	0.000612	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TSHB—hypothyroidism	4.37e-05	0.000568	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—POMC—hypothyroidism	4.25e-05	0.000553	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IGF1—hypothyroidism	4.09e-05	0.000532	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3C2A—hypothyroidism	3.9e-05	0.000507	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	3.85e-05	0.0005	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TSHB—hypothyroidism	3.59e-05	0.000467	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TSHB—hypothyroidism	3.56e-05	0.000463	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SLC5A5—hypothyroidism	3.27e-05	0.000426	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	3.2e-05	0.000416	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—POMC—hypothyroidism	3.18e-05	0.000413	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3C2A—hypothyroidism	3.17e-05	0.000412	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	3.13e-05	0.000407	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1—hypothyroidism	3.06e-05	0.000397	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TSHB—hypothyroidism	3.04e-05	0.000395	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3C2A—hypothyroidism	2.71e-05	0.000352	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SLC5A5—hypothyroidism	2.69e-05	0.000349	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—POMC—hypothyroidism	2.67e-05	0.000348	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SLC5A5—hypothyroidism	2.66e-05	0.000346	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—POMC—hypothyroidism	2.65e-05	0.000345	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TSHB—hypothyroidism	2.35e-05	0.000305	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SLC5A5—hypothyroidism	2.28e-05	0.000296	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3C2A—hypothyroidism	2.09e-05	0.000272	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SLC5A5—hypothyroidism	1.76e-05	0.000228	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—POMC—hypothyroidism	1.71e-05	0.000223	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—POMC—hypothyroidism	1.41e-05	0.000183	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—POMC—hypothyroidism	1.39e-05	0.000181	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—POMC—hypothyroidism	1.19e-05	0.000155	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—POMC—hypothyroidism	9.19e-06	0.000119	CbGpPWpGaD
